カテゴリー： 世界, 医療/バイオ, LP Information

世界の腫瘍免疫療法薬市場予測 2023年-2029年

【英語タイトル】Global Tumor Immunotherapy Drugs Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC01227）・商品コード：LP23DC01227
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：112
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の腫瘍免疫療法薬市場」は、過去の販売実績から2022年の世界の腫瘍免疫療法薬の総販売量を検討し、2023年から2029年の予測される腫瘍免疫療法薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の腫瘍免疫療法薬の市場規模を掲載し、XXX百万米ドル規模の世界の腫瘍免疫療法薬市場の詳細な分析を提供します。本インサイトレポートは、世界の腫瘍免疫療法薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の腫瘍免疫療法薬市場における各社の独自のポジションをより深く理解するために、腫瘍免疫療法薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の腫瘍免疫療法薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。腫瘍免疫療法薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。腫瘍免疫療法薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。腫瘍免疫療法薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

腫瘍免疫療法薬の世界主要メーカーとしては、Bristol Myer Squibb、 AstraZeneca、 Merck、 Roche / Genentech、 Ono Pharmaceutical、 Regeneron、 Innovent、 Hengrui Medicine、 Junshi Biosciences、 Pfizer, Inc、 F. Hoffmann-La Roche Ltd、 Incyte Corporation、 NewLink Genetics Corporation、 Celldex Therapeutics, Inc、 GlaxoSmithKlineなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の腫瘍免疫療法薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では腫瘍免疫療法薬市場をセグメンテーションし、種類別 (免疫チェックポイント阻害剤、腫瘍ワクチン、養子免疫療法、非特異的免疫調節剤)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：免疫チェックポイント阻害剤、腫瘍ワクチン、養子免疫療法、非特異的免疫調節剤

・用途別区分：病院、診療所、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の腫瘍免疫療法薬市場の10年間の市場状況・展望は？
・世界および地域別に見た腫瘍免疫療法薬市場成長の要因は何か？
・腫瘍免疫療法薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・腫瘍免疫療法薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：腫瘍免疫療法薬の年間販売量2018-2029、地域別現状・将来分析
・腫瘍免疫療法薬の種類別セグメント：免疫チェックポイント阻害剤、腫瘍ワクチン、養子免疫療法、非特異的免疫調節剤
・腫瘍免疫療法薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・腫瘍免疫療法薬の用途別セグメント：病院、診療所、その他
・腫瘍免疫療法薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の腫瘍免疫療法薬市場
・企業別のグローバル腫瘍免疫療法薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の腫瘍免疫療法薬の年間売上：2018-2023年の売上、市場シェア
・企業別の腫瘍免疫療法薬販売価格
・主要企業の腫瘍免疫療法薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

腫瘍免疫療法薬の地域別レビュー
・地域別の腫瘍免疫療法薬市場規模2018-2023：年間販売量、売上
・主要国別の腫瘍免疫療法薬市場規模2018-2023：年間販売量、売上
・南北アメリカの腫瘍免疫療法薬販売の成長
・アジア太平洋の腫瘍免疫療法薬販売の成長
・ヨーロッパの腫瘍免疫療法薬販売の成長
・中東・アフリカの腫瘍免疫療法薬販売の成長

南北アメリカ市場
・南北アメリカの国別の腫瘍免疫療法薬販売量、売上（2018-2023）
・南北アメリカの腫瘍免疫療法薬の種類別販売量
・南北アメリカの腫瘍免疫療法薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の腫瘍免疫療法薬販売量、売上（2018-2023）
・アジア太平洋の腫瘍免疫療法薬の種類別販売量
・アジア太平洋の腫瘍免疫療法薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の腫瘍免疫療法薬販売量、売上（2018-2023）
・ヨーロッパの腫瘍免疫療法薬の種類別販売量
・ヨーロッパの腫瘍免疫療法薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の腫瘍免疫療法薬販売量、売上（2018-2023）
・中東・アフリカの腫瘍免疫療法薬の種類別販売量
・中東・アフリカの腫瘍免疫療法薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・腫瘍免疫療法薬の製造コスト構造分析
・腫瘍免疫療法薬の製造プロセス分析
・腫瘍免疫療法薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・腫瘍免疫療法薬の主要なグローバル販売業者
・腫瘍免疫療法薬の主要なグローバル顧客

地域別の腫瘍免疫療法薬市場予測レビュー
・地域別の腫瘍免疫療法薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・腫瘍免疫療法薬の種類別市場規模予測
・腫瘍免疫療法薬の用途別市場規模予測

主要企業分析
Bristol Myer Squibb、 AstraZeneca、 Merck、 Roche / Genentech、 Ono Pharmaceutical、 Regeneron、 Innovent、 Hengrui Medicine、 Junshi Biosciences、 Pfizer, Inc、 F. Hoffmann-La Roche Ltd、 Incyte Corporation、 NewLink Genetics Corporation、 Celldex Therapeutics, Inc、 GlaxoSmithKline
・企業情報
・腫瘍免疫療法薬製品
・腫瘍免疫療法薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Tumor Immunotherapy Drugs market size is projected to grow from US$ 41670 million in 2022 to US$ 77330 million in 2029; it is expected to grow at a CAGR of 9.2% from 2023 to 2029.
United States market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Immunotherapy Drugs players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient’s own immune system.
LPI (LP Information)’ newest research report, the “Tumor Immunotherapy Drugs Industry Forecast” looks at past sales and reviews total world Tumor Immunotherapy Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Immunotherapy Drugs sales for 2023 through 2029. With Tumor Immunotherapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunotherapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Tumor Immunotherapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immunotherapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunotherapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunotherapy Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunotherapy Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunotherapy Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Immune Checkpoint Inhibitors
Tumor Vaccine
Adoptive Immunotherapy
Non-specific Immunomodulator
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tumor Immunotherapy Drugs market?
What factors are driving Tumor Immunotherapy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Immunotherapy Drugs market opportunities vary by end market size?
How does Tumor Immunotherapy Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Immunotherapy Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Tumor Immunotherapy Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Tumor Immunotherapy Drugs by Country/Region, 2018, 2022 & 2029
2.2 Tumor Immunotherapy Drugs Segment by Type
2.2.1 Immune Checkpoint Inhibitors
2.2.2 Tumor Vaccine
2.2.3 Adoptive Immunotherapy
2.2.4 Non-specific Immunomodulator
2.3 Tumor Immunotherapy Drugs Sales by Type
2.3.1 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Tumor Immunotherapy Drugs Sale Price by Type (2018-2023)
2.4 Tumor Immunotherapy Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Tumor Immunotherapy Drugs Sales by Application
2.5.1 Global Tumor Immunotherapy Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Tumor Immunotherapy Drugs Sale Price by Application (2018-2023)
3 Global Tumor Immunotherapy Drugs by Company
3.1 Global Tumor Immunotherapy Drugs Breakdown Data by Company
3.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Tumor Immunotherapy Drugs Sales Market Share by Company (2018-2023)
3.2 Global Tumor Immunotherapy Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Tumor Immunotherapy Drugs Revenue by Company (2018-2023)
3.2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Tumor Immunotherapy Drugs Sale Price by Company
3.4 Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Immunotherapy Drugs Product Location Distribution
3.4.2 Players Tumor Immunotherapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Tumor Immunotherapy Drugs by Geographic Region
4.1 World Historic Tumor Immunotherapy Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Tumor Immunotherapy Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Tumor Immunotherapy Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Tumor Immunotherapy Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Tumor Immunotherapy Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Tumor Immunotherapy Drugs Sales Growth
4.4 APAC Tumor Immunotherapy Drugs Sales Growth
4.5 Europe Tumor Immunotherapy Drugs Sales Growth
4.6 Middle East & Africa Tumor Immunotherapy Drugs Sales Growth
5 Americas
5.1 Americas Tumor Immunotherapy Drugs Sales by Country
5.1.1 Americas Tumor Immunotherapy Drugs Sales by Country (2018-2023)
5.1.2 Americas Tumor Immunotherapy Drugs Revenue by Country (2018-2023)
5.2 Americas Tumor Immunotherapy Drugs Sales by Type
5.3 Americas Tumor Immunotherapy Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunotherapy Drugs Sales by Region
6.1.1 APAC Tumor Immunotherapy Drugs Sales by Region (2018-2023)
6.1.2 APAC Tumor Immunotherapy Drugs Revenue by Region (2018-2023)
6.2 APAC Tumor Immunotherapy Drugs Sales by Type
6.3 APAC Tumor Immunotherapy Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tumor Immunotherapy Drugs by Country
7.1.1 Europe Tumor Immunotherapy Drugs Sales by Country (2018-2023)
7.1.2 Europe Tumor Immunotherapy Drugs Revenue by Country (2018-2023)
7.2 Europe Tumor Immunotherapy Drugs Sales by Type
7.3 Europe Tumor Immunotherapy Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Immunotherapy Drugs by Country
8.1.1 Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Tumor Immunotherapy Drugs Sales by Type
8.3 Middle East & Africa Tumor Immunotherapy Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs
10.3 Manufacturing Process Analysis of Tumor Immunotherapy Drugs
10.4 Industry Chain Structure of Tumor Immunotherapy Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Immunotherapy Drugs Distributors
11.3 Tumor Immunotherapy Drugs Customer
12 World Forecast Review for Tumor Immunotherapy Drugs by Geographic Region
12.1 Global Tumor Immunotherapy Drugs Market Size Forecast by Region
12.1.1 Global Tumor Immunotherapy Drugs Forecast by Region (2024-2029)
12.1.2 Global Tumor Immunotherapy Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumor Immunotherapy Drugs Forecast by Type
12.7 Global Tumor Immunotherapy Drugs Forecast by Application
13 Key Players Analysis
13.1 Bristol Myer Squibb
13.1.1 Bristol Myer Squibb Company Information
13.1.2 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Bristol Myer Squibb Main Business Overview
13.1.5 Bristol Myer Squibb Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Roche / Genentech
13.4.1 Roche / Genentech Company Information
13.4.2 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Roche / Genentech Main Business Overview
13.4.5 Roche / Genentech Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.7.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
13.10 Pfizer, Inc
13.10.1 Pfizer, Inc Company Information
13.10.2 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Pfizer, Inc Main Business Overview
13.10.5 Pfizer, Inc Latest Developments
13.11 F. Hoffmann-La Roche Ltd
13.11.1 F. Hoffmann-La Roche Ltd Company Information
13.11.2 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.11.5 F. Hoffmann-La Roche Ltd Latest Developments
13.12 Incyte Corporation
13.12.1 Incyte Corporation Company Information
13.12.2 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Incyte Corporation Main Business Overview
13.12.5 Incyte Corporation Latest Developments
13.13 NewLink Genetics Corporation
13.13.1 NewLink Genetics Corporation Company Information
13.13.2 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NewLink Genetics Corporation Main Business Overview
13.13.5 NewLink Genetics Corporation Latest Developments
13.14 Celldex Therapeutics, Inc
13.14.1 Celldex Therapeutics, Inc Company Information
13.14.2 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Celldex Therapeutics, Inc Main Business Overview
13.14.5 Celldex Therapeutics, Inc Latest Developments
13.15 GlaxoSmithKline
13.15.1 GlaxoSmithKline Company Information
13.15.2 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 GlaxoSmithKline Main Business Overview
13.15.5 GlaxoSmithKline Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Tumor Immunotherapy Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Tumor Immunotherapy Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Immune Checkpoint Inhibitors
Table 4. Major Players of Tumor Vaccine
Table 5. Major Players of Adoptive Immunotherapy
Table 6. Major Players of Non-specific Immunomodulator
Table 7. Global Tumor Immunotherapy Drugs Sales by Type (2018-2023) & (K Units)
Table 8. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
Table 9. Global Tumor Immunotherapy Drugs Revenue by Type (2018-2023) & ($ million)
Table 10. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2018-2023)
Table 11. Global Tumor Immunotherapy Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Tumor Immunotherapy Drugs Sales by Application (2018-2023) & (K Units)
Table 13. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2023)
Table 14. Global Tumor Immunotherapy Drugs Revenue by Application (2018-2023)
Table 15. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2018-2023)
Table 16. Global Tumor Immunotherapy Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Tumor Immunotherapy Drugs Sales by Company (2018-2023) & (K Units)
Table 18. Global Tumor Immunotherapy Drugs Sales Market Share by Company (2018-2023)
Table 19. Global Tumor Immunotherapy Drugs Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2018-2023)
Table 21. Global Tumor Immunotherapy Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution and Sales Area
Table 23. Players Tumor Immunotherapy Drugs Products Offered
Table 24. Tumor Immunotherapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Tumor Immunotherapy Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Tumor Immunotherapy Drugs Sales Market Share Geographic Region (2018-2023)
Table 29. Global Tumor Immunotherapy Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Tumor Immunotherapy Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Tumor Immunotherapy Drugs Sales Market Share by Country/Region (2018-2023)
Table 33. Global Tumor Immunotherapy Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Tumor Immunotherapy Drugs Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Tumor Immunotherapy Drugs Sales by Country (2018-2023) & (K Units)
Table 36. Americas Tumor Immunotherapy Drugs Sales Market Share by Country (2018-2023)
Table 37. Americas Tumor Immunotherapy Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country (2018-2023)
Table 39. Americas Tumor Immunotherapy Drugs Sales by Type (2018-2023) & (K Units)
Table 40. Americas Tumor Immunotherapy Drugs Sales by Application (2018-2023) & (K Units)
Table 41. APAC Tumor Immunotherapy Drugs Sales by Region (2018-2023) & (K Units)
Table 42. APAC Tumor Immunotherapy Drugs Sales Market Share by Region (2018-2023)
Table 43. APAC Tumor Immunotherapy Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Tumor Immunotherapy Drugs Revenue Market Share by Region (2018-2023)
Table 45. APAC Tumor Immunotherapy Drugs Sales by Type (2018-2023) & (K Units)
Table 46. APAC Tumor Immunotherapy Drugs Sales by Application (2018-2023) & (K Units)
Table 47. Europe Tumor Immunotherapy Drugs Sales by Country (2018-2023) & (K Units)
Table 48. Europe Tumor Immunotherapy Drugs Sales Market Share by Country (2018-2023)
Table 49. Europe Tumor Immunotherapy Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country (2018-2023)
Table 51. Europe Tumor Immunotherapy Drugs Sales by Type (2018-2023) & (K Units)
Table 52. Europe Tumor Immunotherapy Drugs Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Tumor Immunotherapy Drugs Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Tumor Immunotherapy Drugs Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Tumor Immunotherapy Drugs
Table 60. Key Market Challenges & Risks of Tumor Immunotherapy Drugs
Table 61. Key Industry Trends of Tumor Immunotherapy Drugs
Table 62. Tumor Immunotherapy Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Tumor Immunotherapy Drugs Distributors List
Table 65. Tumor Immunotherapy Drugs Customer List
Table 66. Global Tumor Immunotherapy Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Tumor Immunotherapy Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Tumor Immunotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Tumor Immunotherapy Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Tumor Immunotherapy Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Tumor Immunotherapy Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Tumor Immunotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Tumor Immunotherapy Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Tumor Immunotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Tumor Immunotherapy Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Tumor Immunotherapy Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Tumor Immunotherapy Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Tumor Immunotherapy Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Tumor Immunotherapy Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Bristol Myer Squibb Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 82. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Bristol Myer Squibb Main Business
Table 84. Bristol Myer Squibb Latest Developments
Table 85. AstraZeneca Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 87. AstraZeneca Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Merck Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 92. Merck Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Merck Main Business
Table 94. Merck Latest Developments
Table 95. Roche / Genentech Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 97. Roche / Genentech Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Roche / Genentech Main Business
Table 99. Roche / Genentech Latest Developments
Table 100. Ono Pharmaceutical Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 102. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Ono Pharmaceutical Main Business
Table 104. Ono Pharmaceutical Latest Developments
Table 105. Regeneron Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 107. Regeneron Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Regeneron Main Business
Table 109. Regeneron Latest Developments
Table 110. Innovent Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 112. Innovent Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Innovent Main Business
Table 114. Innovent Latest Developments
Table 115. Hengrui Medicine Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 117. Hengrui Medicine Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Hengrui Medicine Main Business
Table 119. Hengrui Medicine Latest Developments
Table 120. Junshi Biosciences Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 122. Junshi Biosciences Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Junshi Biosciences Main Business
Table 124. Junshi Biosciences Latest Developments
Table 125. Pfizer, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 127. Pfizer, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Pfizer, Inc Main Business
Table 129. Pfizer, Inc Latest Developments
Table 130. F. Hoffmann-La Roche Ltd Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 132. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. F. Hoffmann-La Roche Ltd Main Business
Table 134. F. Hoffmann-La Roche Ltd Latest Developments
Table 135. Incyte Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 137. Incyte Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Incyte Corporation Main Business
Table 139. Incyte Corporation Latest Developments
Table 140. NewLink Genetics Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 142. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. NewLink Genetics Corporation Main Business
Table 144. NewLink Genetics Corporation Latest Developments
Table 145. Celldex Therapeutics, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 147. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Celldex Therapeutics, Inc Main Business
Table 149. Celldex Therapeutics, Inc Latest Developments
Table 150. GlaxoSmithKline Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 152. GlaxoSmithKline Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. GlaxoSmithKline Main Business
Table 154. GlaxoSmithKline Latest Developments
List of Figures
Figure 1. Picture of Tumor Immunotherapy Drugs
Figure 2. Tumor Immunotherapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumor Immunotherapy Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Tumor Immunotherapy Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Tumor Immunotherapy Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Immune Checkpoint Inhibitors
Figure 10. Product Picture of Tumor Vaccine
Figure 11. Product Picture of Adoptive Immunotherapy
Figure 12. Product Picture of Non-specific Immunomodulator
Figure 13. Global Tumor Immunotherapy Drugs Sales Market Share by Type in 2022
Figure 14. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2018-2023)
Figure 15. Tumor Immunotherapy Drugs Consumed in Hospital
Figure 16. Global Tumor Immunotherapy Drugs Market: Hospital (2018-2023) & (K Units)
Figure 17. Tumor Immunotherapy Drugs Consumed in Clinic
Figure 18. Global Tumor Immunotherapy Drugs Market: Clinic (2018-2023) & (K Units)
Figure 19. Tumor Immunotherapy Drugs Consumed in Other
Figure 20. Global Tumor Immunotherapy Drugs Market: Other (2018-2023) & (K Units)
Figure 21. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2022)
Figure 22. Global Tumor Immunotherapy Drugs Revenue Market Share by Application in 2022
Figure 23. Tumor Immunotherapy Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global Tumor Immunotherapy Drugs Sales Market Share by Company in 2022
Figure 25. Tumor Immunotherapy Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Tumor Immunotherapy Drugs Revenue Market Share by Company in 2022
Figure 27. Global Tumor Immunotherapy Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Tumor Immunotherapy Drugs Sales 2018-2023 (K Units)
Figure 30. Americas Tumor Immunotherapy Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC Tumor Immunotherapy Drugs Sales 2018-2023 (K Units)
Figure 32. APAC Tumor Immunotherapy Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe Tumor Immunotherapy Drugs Sales 2018-2023 (K Units)
Figure 34. Europe Tumor Immunotherapy Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Tumor Immunotherapy Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Tumor Immunotherapy Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas Tumor Immunotherapy Drugs Sales Market Share by Country in 2022
Figure 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country in 2022
Figure 39. Americas Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Tumor Immunotherapy Drugs Sales Market Share by Region in 2022
Figure 46. APAC Tumor Immunotherapy Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2023)
Figure 49. China Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Tumor Immunotherapy Drugs Sales Market Share by Country in 2022
Figure 57. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country in 2022
Figure 58. Europe Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Tumor Immunotherapy Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2022
Figure 75. Manufacturing Process Analysis of Tumor Immunotherapy Drugs
Figure 76. Industry Chain Structure of Tumor Immunotherapy Drugs
Figure 77. Channels of Distribution
Figure 78. Global Tumor Immunotherapy Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の腫瘍免疫療法薬市場予測 2023年-2029年] (コード：LP23DC01227)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の腫瘍免疫療法薬市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の筋骨格系腫瘍治療市場予測 2023年-2029年
  • 世界の腫瘍凍結アブレーション装置市場予測 2023年-2029年
  • 世界の腫瘍免疫チェックポイント阻害剤療法市場予測 2023年-2029年
  • 世界の腫瘍マイクロ波アブレーション装置市場予測 2023年-2029年
  • 世界の腫瘍セルソーター市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆